Table 3.
Resistance to multiple antimicrobial classes is strongly associated with the presence of the RE-cmeABC in Campylobacter jejuni and Campylobacter coli genomes
| Campylobacter jejuni | ||||||||
|---|---|---|---|---|---|---|---|---|
| Number antimicrobial-resistant classes | Genotype | Phenotype | ||||||
| Total number of isolates | RE-cmeABC (% (n/N)) | Overexpressed cmeABC (% (n/N))a | RE-cmeABC and overexpressed cmeABC (% (n/N))a | Total number of isolates | RE-cmeABC (% (n/N)) | Overexpressed cmeABC (% (n/N))a | RE-cmeABC and overexpressed cmeABC (% (n/N))a | |
| 0 | 25 | 0% (0/25) | 0% (0/23) | 0% (0/23) | 20 | 0% (0/20) | 5.0% (1/20) | 0% (0/20) |
| 1 | 25 | 0% (0/25) | 4.2% (1/24) | 0% (0/24) | 24 | 12.5% (3/24) | 13.0% (3/23) | 8.7% (2/23) |
| 2 | 3 | 33.3% (1/3) | 33.3% (1/3) | 33.3% (1/3) | 25 | 52.0% (13/25) | 33.3% (8/24) | 25.0% (6/24) |
| 3 | 19 | 63.2% (12/19) | 38.9% (7/18) | 33.3% (6/18) | 14 | 64.3% (9/14) | 25.0% (3/12) | 25.0% (3/12) |
| 4 | 23 | 87.0% (20/23) | 56.5% (13/23) | 47.8% (11/23) | 13 | 69.2% (9/13) | 61.5% (8/13) | 61.5% (8/13) |
| 5 | 2 | 100% (2/2) | 100% (2/2) | 100% (2/2) | 1 | 100% (1/1) | 100% (1/1) | 100% (1/1) |
| Total | 97 | 97 | 93 | 93 | 97 | 97 | 93 | 93 |
| Campylobacter coli | ||||||||
| Number antimicrobial resistant classes | Genotype | Phenotype | ||||||
| Total number of isolates | RE-cmeABC (% (n/N)) | Overexpressed cmeABC (% (n/N))b | RE-cmeABC and overexpressed cmeABC (% (n/N))b | Total number of isolates | RE-cmeABC (% (n/N)) | Overexpressed cmeABC (% (n/N))b | RE-cmeABC and overexpressed cmeABC (% (n/N))b | |
| 0 | 6 | 0% (0/6) | 0% (0/6) | 0% (0/6) | 11 | 0% (0/11) | 9.1% (1/11) | 0% (0/11) |
| 1 | 7 | 0% (0/7) | 14.3% (1/7) | 0% (0/7) | 9 | 11.1% (1/9) | 0% (0/9) | 0% (0/9) |
| 2 | 9 | 11.1% (1/9) | 0% (0/9) | 0% (0/9) | 12 | 25.0% (3/12) | 8.3% (1/12) | 8.3% (1/12) |
| 3 | 10 | 0% (0/10) | 20/0% (2/10) | 0% (0/10) | 6 | 0% (0/6) | 0% (0/6) | 0% (0/6) |
| 4 | 5 | 60.0% (3/5) | 20.0% (1/5) | 20.0% (1/5) | 6 | 50.0% (3/6) | 66.7% (4/6) | 33.3% (2/6) |
| 5 | 30 | 26.7% (8/30) | 35.7% (10/28) | 14.3% (4/28) | 23 | 21.7% (5/23) | 38.1% (8/21) | 18.2% (2/21) |
| Total | 67 | 67 | 65 | 65 | 67 | 67 | 64 | 64 |
NOTE: n = number of isolates with the genomic determinant; N = total number of isolates for which the genomic determinant could be evaluated.
a
N differs from total number of isolates given that for four samples the status of the cmeR binding site could not be determined.
b
N differs from total number of isolates given that for two samples the status of the cmeR binding site could not be determined.